Key facts
- This page summarizes Ian Ying Woo's Form 4 filing for NovaBridge Biosciences (NBP).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 Oct 2026, 16:15.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Footnote F1
The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
Footnote F2
Reported securities are represented by 5,770 ADSs.
Footnote F3
Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.
Footnote F4
Reported securities represent ADSs.
Footnote F5
On October 15, 2025, the Reporting Person was granted 17,310 restricted share units ("RSUs"). The RSUs vest or shall vest over three years in equal annual installments on October 15, 2026, 2027 and 2028.
Footnote F6
Reported securities represent ADSs.